SOLIFENACIN PMCS 10MG õhukese polümeerikattega tablett Eesti - eesti - Ravimiamet

solifenacin pmcs 10mg õhukese polümeerikattega tablett

pro.med.cs praha a.s. - solifenatsiin - õhukese polümeerikattega tablett - 10mg 20tk; 10mg 90tk; 10mg 30tk; 10mg 100tk; 10mg 60tk; 10mg 50tk; 10mg 10tk

Cevac IBD 2512 L suspensiooni lüofilisaat Eesti - eesti - Ravimiamet

cevac ibd 2512 l suspensiooni lüofilisaat

ceva santé animale - lindude nakkava bursiidi (gumboro) viirusvaktsiin - suspensiooni lüofilisaat - 1annus 1000annus 1tk; 1annus 2500annus 20tk; 1annus 5000annus 20tk

NATRII CHLORIDUM BAXTER infusioonilahus Eesti - eesti - Ravimiamet

natrii chloridum baxter infusioonilahus

baxter healthcare limited - naatriumkloriid - infusioonilahus - 0,9% 50ml 50tk; 0,9% 1000ml 10tk; 0,9% 50ml 1tk; 0,9% 100ml 1tk; 0,9% 250ml 1tk; 0,9% 500ml 1tk

RINGER LACTATE BAXTER infusioonilahus Eesti - eesti - Ravimiamet

ringer lactate baxter infusioonilahus

baxter healthcare limited - elektrolüüdid - infusioonilahus - 250ml 30tk; 500ml 1tk; 1000ml 10tk; 250ml 1tk; 1000ml 1tk

GLUCOSE BAXTER 5% infusioonilahus Eesti - eesti - Ravimiamet

glucose baxter 5% infusioonilahus

baxter healthcare limited - süsivesikud - infusioonilahus - 5% 250ml 30tk; 5% 100ml 1tk; 5% 100ml 50tk; 5% 500ml 20tk; 5% 1000ml 10tk; 5% 50ml 1tk

Alzane süstelahus Eesti - eesti - Ravimiamet

alzane süstelahus

laboratorios syva s.a. - atipamesool - süstelahus - 5mg 1ml 10ml 10tk; 5mg 1ml 10ml 5tk

Spikevax (previously COVID-19 Vaccine Moderna) Euroopa Liit - eesti - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaktsiinid - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.